Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 12/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639007 | 0.90 | SUV39H2 (0.60) | SUV39H2MAPTSMN1; SMN2ALKALDH1A1 | |
| SCHEMBL15797078 | 0.87 | MAPT (0.72) | MAPTSMN1; SMN2ALDH1A1LMNAMAPK1 | |
| SCHEMBL30208188 | 0.87 | MAPT (0.72) | MAPTSMN1; SMN2ALDH1A1LMNAMAPK1 | |
| SCHEMBL18013315 | 0.87 | PDK2 (0.53) | SUV39H2MAPTSMN1; SMN2ALKALDH1A1 | |
| SCHEMBL13162408 | 0.86 | SUV39H2 (0.61) | SUV39H2MAPTSMN1; SMN2ALKALDH1A1 | |
| SCHEMBL21533625 | 0.86 | MAPT (0.63) | SUV39H2MAPTSMN1; SMN2ALKALDH1A1 | |
| SCHEMBL15862951 | 0.85 | LMNA (0.54) | SUV39H2MAPTSMN1; SMN2ALKALDH1A1 | |
| SCHEMBL31195734 | 0.85 | ALK (0.55) | SUV39H2MAPTSMN1; SMN2ALKALDH1A1 | |
| SCHEMBL4930175 | 0.85 | MAPT (0.58) | SUV39H2MAPTSMN1; SMN2ALKALDH1A1 | |
| SCHEMBL18588079 | 0.84 | MAPT (0.56) | SUV39H2MAPTSMN1; SMN2ALKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1396487-B1 | PHENYLPYRIDINE CARBONYL PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2008-12-10 | — | — | EP | disclosed |
| US-7196080-B2 | Respiratory system disordeers; chronic obstructive pulminary disease | ASTELLAS PHARMA INC. (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20040192701-A1 | Phenlypyridine carbonyl piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2004-09-30 | — | — | US | disclosed |
| EP-1396487-A1 | PHENYLPYRIDINE CARBONYL PIPERAZINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192701-A1 | Phenlypyridine carbonyl piperazine derivative | PDE5A, PDE4A, PDE3B | SUV39H2 317/4885MAPT 4798/4885SMN1; SMN2 4250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.